CA2341358C - Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor - Google Patents
Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor Download PDFInfo
- Publication number
- CA2341358C CA2341358C CA2341358A CA2341358A CA2341358C CA 2341358 C CA2341358 C CA 2341358C CA 2341358 A CA2341358 A CA 2341358A CA 2341358 A CA2341358 A CA 2341358A CA 2341358 C CA2341358 C CA 2341358C
- Authority
- CA
- Canada
- Prior art keywords
- microparticles
- antigen
- fha
- ptd
- plga
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 52
- 230000001939 inductive effect Effects 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title abstract description 36
- 238000009472 formulation Methods 0.000 title abstract description 26
- 229960005486 vaccine Drugs 0.000 title abstract description 25
- 230000021633 leukocyte mediated immunity Effects 0.000 title description 3
- 239000000427 antigen Substances 0.000 claims abstract description 216
- 108091007433 antigens Proteins 0.000 claims abstract description 216
- 102000036639 antigens Human genes 0.000 claims abstract description 216
- 239000011859 microparticle Substances 0.000 claims abstract description 144
- 230000028993 immune response Effects 0.000 claims abstract description 42
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 41
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 29
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 29
- 238000007912 intraperitoneal administration Methods 0.000 claims description 45
- 238000007920 subcutaneous administration Methods 0.000 claims description 26
- 230000036039 immunity Effects 0.000 claims description 15
- 238000000935 solvent evaporation Methods 0.000 claims description 13
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 10
- 230000000241 respiratory effect Effects 0.000 claims description 10
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 9
- 108010021711 pertactin Proteins 0.000 claims description 8
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 5
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 208000005176 Hepatitis C Diseases 0.000 claims description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- 208000000474 Poliomyelitis Diseases 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 4
- 241000607142 Salmonella Species 0.000 claims description 4
- 241000607768 Shigella Species 0.000 claims description 4
- 208000003152 Yellow Fever Diseases 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 208000005252 hepatitis A Diseases 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 206010008631 Cholera Diseases 0.000 claims description 3
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 59
- 239000002105 nanoparticle Substances 0.000 abstract description 51
- 238000007911 parenteral administration Methods 0.000 abstract description 13
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 145
- 241000699670 Mus sp. Species 0.000 description 71
- 239000002245 particle Substances 0.000 description 56
- 239000000243 solution Substances 0.000 description 47
- 229940037003 alum Drugs 0.000 description 44
- 238000002649 immunization Methods 0.000 description 42
- 238000011282 treatment Methods 0.000 description 32
- 229920000642 polymer Polymers 0.000 description 27
- 238000011068 loading method Methods 0.000 description 21
- 210000004989 spleen cell Anatomy 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 19
- 108010002616 Interleukin-5 Proteins 0.000 description 19
- 102000000743 Interleukin-5 Human genes 0.000 description 19
- 239000004372 Polyvinyl alcohol Substances 0.000 description 19
- 229940100602 interleukin-5 Drugs 0.000 description 19
- 229940068984 polyvinyl alcohol Drugs 0.000 description 19
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 description 19
- 229920000747 poly(lactic acid) Polymers 0.000 description 16
- 201000005702 Pertussis Diseases 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 12
- 239000004005 microsphere Substances 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000003389 potentiating effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000005867 T cell response Effects 0.000 description 9
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 238000004626 scanning electron microscopy Methods 0.000 description 8
- 238000001694 spray drying Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000016396 cytokine production Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000029069 type 2 immune response Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000029662 T-helper 1 type immune response Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000007762 w/o emulsion Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000005354 coacervation Methods 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 229940066827 pertussis vaccine Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000002050 diffraction method Methods 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000001986 peyer's patch Anatomy 0.000 description 3
- 230000009696 proliferative response Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000002569 water oil cream Substances 0.000 description 3
- 238000000035 BCA protein assay Methods 0.000 description 2
- -1 IFN-y Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012867 bioactive agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000022023 interleukin-5 production Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- XTLNYNMNUCLWEZ-UHFFFAOYSA-N ethanol;propan-2-one Chemical compound CCO.CC(C)=O XTLNYNMNUCLWEZ-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000004726 long-term protective immunity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- BMLIZLVNXIYGCK-UHFFFAOYSA-N monuron Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C=C1 BMLIZLVNXIYGCK-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2731995A CA2731995C (en) | 1998-09-01 | 1999-08-31 | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9876098P | 1998-09-01 | 1998-09-01 | |
| US60/098,760 | 1998-09-01 | ||
| PCT/IE1999/000087 WO2000012125A1 (en) | 1998-09-01 | 1999-08-31 | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2731995A Division CA2731995C (en) | 1998-09-01 | 1999-08-31 | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2341358A1 CA2341358A1 (en) | 2000-03-09 |
| CA2341358C true CA2341358C (en) | 2011-04-26 |
Family
ID=22270768
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2341358A Expired - Fee Related CA2341358C (en) | 1998-09-01 | 1999-08-31 | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| CA2731995A Expired - Fee Related CA2731995C (en) | 1998-09-01 | 1999-08-31 | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2731995A Expired - Fee Related CA2731995C (en) | 1998-09-01 | 1999-08-31 | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1107783B1 (enExample) |
| JP (1) | JP4526708B2 (enExample) |
| AT (1) | ATE322285T1 (enExample) |
| AU (1) | AU5441299A (enExample) |
| CA (2) | CA2341358C (enExample) |
| DE (1) | DE69930753D1 (enExample) |
| WO (1) | WO2000012125A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995017167A1 (de) | 1993-12-23 | 1995-06-29 | Gff Gesellschaft Zur Förderung Der Industrieorientierten Forschung | Verfahren zur potenzierung der immunologischen antwort |
| US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
| US6977085B2 (en) | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
| US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
| US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
| US7193084B2 (en) | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
| US6869617B2 (en) | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
| US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| IL160570A0 (en) | 2001-09-26 | 2004-07-25 | Baxter Int | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
| US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
| JP4851067B2 (ja) * | 2004-01-28 | 2012-01-11 | ホソカワミクロン株式会社 | ナノ粒子含有組成物およびその製造方法 |
| ES2246695B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Composicion estimuladora de la respuesta inmunitaria que comprende nanoparticulas a base de un copolimero de metil vinil eter y anhidrido maleico. |
| CN101646455A (zh) * | 2007-02-07 | 2010-02-10 | 财团法人阪大微生物病研究会 | 用于癌症的治疗剂 |
| WO2008117313A1 (en) * | 2007-03-28 | 2008-10-02 | National Institute Of Immunology | Polymer particles based vaccine |
| JP6910949B2 (ja) * | 2014-08-14 | 2021-07-28 | ブラウン ユニバーシティ | タンパク質を安定化させ、送達するための組成物 |
| ES2865375T3 (es) * | 2014-11-05 | 2021-10-15 | Selecta Biosciences Inc | Métodos y composiciones relacionadas con nanovehículos sintéticos con rapamicina en un estado sobresaturado estable |
| GB201918963D0 (en) | 2019-12-20 | 2020-02-05 | Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin | Polymeric nanoparticles as vaccine adjuvants |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9209118D0 (en) * | 1992-04-28 | 1992-06-10 | Sb 120 Amsterdam Bv | Vaccine compositions |
| AU4755696A (en) * | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| GB9713156D0 (en) * | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
-
1999
- 1999-08-31 EP EP99940439A patent/EP1107783B1/en not_active Expired - Lifetime
- 1999-08-31 CA CA2341358A patent/CA2341358C/en not_active Expired - Fee Related
- 1999-08-31 WO PCT/IE1999/000087 patent/WO2000012125A1/en not_active Ceased
- 1999-08-31 CA CA2731995A patent/CA2731995C/en not_active Expired - Fee Related
- 1999-08-31 JP JP2000567237A patent/JP4526708B2/ja not_active Expired - Fee Related
- 1999-08-31 AU AU54412/99A patent/AU5441299A/en not_active Abandoned
- 1999-08-31 AT AT99940439T patent/ATE322285T1/de not_active IP Right Cessation
- 1999-08-31 DE DE69930753T patent/DE69930753D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2341358A1 (en) | 2000-03-09 |
| AU5441299A (en) | 2000-03-21 |
| ATE322285T1 (de) | 2006-04-15 |
| JP2002523471A (ja) | 2002-07-30 |
| CA2731995A1 (en) | 2000-03-09 |
| CA2731995C (en) | 2013-05-28 |
| WO2000012125A1 (en) | 2000-03-09 |
| EP1107783A1 (en) | 2001-06-20 |
| EP1107783B1 (en) | 2006-04-05 |
| DE69930753D1 (de) | 2006-05-18 |
| JP4526708B2 (ja) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080254134A1 (en) | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof | |
| US20020009466A1 (en) | Oral vaccine compositions | |
| CA2341358C (en) | Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor | |
| CA2341352C (en) | Oral vaccine compositions | |
| JP2739570B2 (ja) | 単一注射ワクチン剤形 | |
| US5603960A (en) | Preparation of microparticles and method of immunization | |
| Kissel et al. | Injectable biodegradable microspheres for vaccine delivery | |
| Payne et al. | Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery | |
| JP3583128B2 (ja) | ワクチン製剤 | |
| JP2001511148A (ja) | 免疫応答を刺激するための吸着された抗原を有するマイクロパーティクルの使用 | |
| JP2002540076A (ja) | ワクチン組成物 | |
| Jabbal-Gill et al. | Potential of polymeric lamellar substrate particles (PLSP) as adjuvants for vaccines | |
| Jones et al. | Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae | |
| Hanes et al. | Polymer microspheres for vaccine delivery | |
| US20020041879A1 (en) | Immunological response potentiation process | |
| JP2005514326A (ja) | ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法 | |
| Yan et al. | Dependence of ricin toxoid vaccine efficacy on the structure of poly (lactide-co-glycolide) microparticle carriers | |
| Yeh et al. | Inactive Vibrio cholerae whole-cell vaccine-loaded biodegradable microparticles: in vitro release and oral vaccination | |
| WO2005023293A1 (en) | Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere | |
| Nechaeva | Development of oral microencapsulated forms for delivering viral vaccines | |
| Bhagat et al. | Oral vaccination by microspheres | |
| Chadhar et al. | A Review on Novel Delivery Vehicles for Vaccines Development | |
| Khan et al. | Antigen Delivery Systems Used to Induce Immunomodulation | |
| GILLEY et al. | JACQUELINE D. DUNCAN | |
| Opdebeeck | Induce Immunomodulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160831 |